Project Grant R56AI192285
Award Date 8/18/26
Completion Date 7/31/27
Dollars Obligated $638K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Scottsdale, AZ 85259, USA
Similar Awards
- Federal Project Grant Award Summary Mayo Clinic Arizona, a nonprofit academic medical center and research institution, received a $486,109 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award, effective July 1, 2025, through June 30, 2027, supports investigator-initiated biomedical research examining Type 2 immune responses in endotoxemia-induced lung injury. The research project...
- The National Institute of Allergy and Infectious Diseases awarded Mayo Clinic Arizona $197,600 on November 1, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to assess food-specific tolerogenic CD4+ T cells in protection from food allergy. The award funds research into the immunologic mechanisms that regulate food allergy development, with focus on understanding how oral exposure to food antigens protects against allergic sensitization and anaphylaxis compared to...
- The National Institute of Allergy and Infectious Diseases awarded La Jolla Institute for Immunology (doing business as La Jolla Institute for Allergy & Immunology) $764,868 on April 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate house dust-mite allergen-specific T cell subsets in allergy and asthma. The research explores mechanisms and cell types that drive either natural tolerance or allergen sensitization and asthma development, focusing on...
- The National Institute of Allergy and Infectious Diseases awarded the University of Arizona $806,740 on August 12, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to characterize the mechanisms by which natural environmental agents from traditional Amish farms protect the lungs against rhinovirus infection and associated asthma development in children. The research investigates how early-life exposure to cow barn environments and barn-derived substances present...
- The National Institute of Allergy and Infectious Diseases awarded the Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center $245,250 on July 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate how sensory neuron release of substance P stimulates B cell immunoglobulin E production in asthma. The research will examine the mechanism by which the neuropeptide substance P, released from neurons sensitized during asthmatic...
- The National Institute of Allergy and Infectious Diseases awarded Mayo Clinic Arizona $209,765 on May 20, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop and validate TIGIT+ B cell therapy as an immunosuppressive strategy to promote transplantation tolerance and suppress acute graft-versus-host disease. The research tests whether TIGIT+ B cells—generated using a novel replication-incompetent recombinant ADV5 vector (ADV5.K7.TIGIT)—can suppress...
- The National Institute of Allergy and Infectious Diseases awarded the University of Arizona $797,394 under Project Grant R01AI201440 on August 1, 2026, to define mechanistic pathways through which infant gut microbial metabolites affect immune responses to airway viral infection and aeroallergens, and to assess their impact on airway barrier integrity. Funding supports the Allergy and Infectious Diseases Research program (CFDA 93.855). The research builds on preliminary findings from the...
- The National Institute of Allergy and Infectious Diseases awarded Mayo Clinic $443,850 on February 4, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate how intestinal exposure to Candida albicans in early life influences developing immune responses, specifically T cell responses and the differentiation of T helper 17 cells that produce the inflammatory cytokine IL-17. The research addresses the growing epidemic of immune-mediated diseases in...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded the University of Arizona a Project Grant of $3,075,549 under the Allergy and Infectious Diseases Research program (CFDA 93.855) on July 28, 2025, with a completion date of June 30, 2029. This research initiative investigates airway innate immune responses to Coccidioides infection, a serious fungal disease commonly known as valley fever that is expanding geographically across the United States. The research focuses on...
- The National Institute of Allergy and Infectious Diseases awarded Mayo Clinic $624,521 on February 24, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to support research on the regulation of target cell survival by the kinases TBK1 and IKKE in T cell-mediated killing of infected and tumor cells. The research investigates how T cells use interferon-gamma for paracrine killing of target cells, with particular focus on how TBK1 and IKKE regulate susceptibility of B16...